Phase I Study of the Liposomal Formulation of Eribulin (E7389-LF): Results from the Advanced Gastric Cancer Expansion Cohort

PURPOSE: In the dose-expansion part of this open-label, phase I study, we explored the efficacy and safety of E7389-LF (liposomal formulation of eribulin) in Japanese patients with advanced gastric cancer. PATIENTS AND METHODS: Patients with advanced gastric cancer who had been previously treated wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Shitara, Kohei, Hirao, Motohiro, Iwasa, Satoru, Oshima, Takashi, Komatsu, Yoshito, Kawazoe, Akihito, Sato, Yasuyoshi, Hamakawa, Takuya, Yonemori, Kan, Machida, Nozomu, Yuki, Satoshi, Suzuki, Takuya, Okumura, Shiori, Takase, Takao, Semba, Taro, Zimmermann, Bob, Teng, Angela, Yamaguchi, Kensei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Clinical Trials: Targeted Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10102841/
https://www.ncbi.nlm.nih.gov/pubmed/36730323
http://dx.doi.org/10.1158/1078-0432.CCR-22-3027

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10102841/
https://www.ncbi.nlm.nih.gov/pubmed/36730323
http://dx.doi.org/10.1158/1078-0432.CCR-22-3027

Ejemplares similares